Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641765 | 0.76 | NOS1 (0.31) | NOS1NOS3NOS2 | |
| SCHEMBL27725505 | 0.74 | CYP2D6 (0.36) | — | |
| SCHEMBL24187676 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL24187675 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL23794770 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL23794700 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL23794699 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL23794754 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL24187677 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 | |
| SCHEMBL23794753 | 0.74 | CHRM2 (0.33) | NOS1NOS3NOS2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934924-B1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6576642-B2 | Inhibitors of the production of Ig E antibodies, antiallergens | KOWA CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20010039279-A1 | Diamide compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6297283-B1 | EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-0934924-A1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039279-A1 | Diamide compounds and compositions containing the same | HRH4, HRH2, HRH1 | NOS1 898/4885NOS3 1228/4885NOS2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.